CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28627
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # cusatuzumab
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
TNFSF7 / CD27L / CD70
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Endotoxin Level
< 0.001EU/ug,determined by LAL method.
Description
Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
Also known as 'cusatuzumab'.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Also known as 'cusatuzumab'.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Scientific Data Images for CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized
ELISA: CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized[NBP3-28627] -
Immobilized huaman CD70 FC at 4 ug/mL can bind CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized, EC50=0.08279 ug/mL.
Flow Cytometry: CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized[NBP3-28627] -
Human TNFSF7 / CD27L / CD70 CHO-K1 Cell Linewere stained with cusatuzumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS,EC50=0.03451 ug/mL.
Flow Cytometry: CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized[NBP3-28627] -
HL-60 cells were stained with CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2727 ug/mL.Applications for CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Reconstitution
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Formulation
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: CD27 Ligand/TNFSF7
Additional CD27 Ligand/TNFSF7 Products
Product Documents for CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized
Product Specific Notices for CD27 Ligand/TNFSF7/CD70 Antibody (cusatuzumab) - Humanized
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...